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Background: Thyroid cancer incidence is increasing, potentially due to enhanced diagnostic practices. However,
access to healthcare may be dependent on socioeconomic status (SES) and race/ethnicity. Consequently, certain
segments of the population may experience thyroid cancer overdiagnosis as a result of greater access to and use
of enhanced diagnostic technology. The current study examined trends by SES in thyroid cancer incidence at the
census tract level from 1995 to 2008 for the population of Texas, as well as by racial/ethnic subgroup.
Methods: Joinpoint regressions were used to examine incidence trends over time by SES for the study popu-
lation, and for the non-Hispanic white, non-Hispanic black, and Hispanic subgroups separately. Other race/
ethnicities were not adequately represented for subgroup analyses.
Results: There were 22,390 incident thyroid cancer cases (65.0% white, 6.7% black, 24.3% Hispanic, 4.1% Asian/
other races; 85.9% papillary histology). The low SES group experienced a steady increase in incidence since 1995
(6.7% per year, p < 0.05), whereas incidence among the high SES group has increased at a rate of 8.6% per year
since 1999 ( p < 0.05). The joinpoint projected incidence trends for the low and high SES groups were significantly
different ( p = 0.047). Whites experienced a steady increase in incidence over time among both high and low SES
groups (7.6% per year p < 0.05), whereas blacks and Hispanics of higher SES had a much more pronounced
increase in incidence over time relative to their lower SES counterparts (blacks = 12.8% vs. 4.1%; Hispanics =
11.2% vs. 8.3%, p < 0.05). For blacks and Hispanics, joinpoint projected incidence trends for the low and high SES
groups were significantly different from one another ( p < 0.001–0.004).
Conclusions: These results identify groups experiencing the greatest problem of increasing thyroid cancer in-
cidence, and raise concern that greater access to healthcare may be accompanied by thyroid cancer over-
diagnosis. A dual focus on delineating and preventing disease-related causal factors and focusing clinical
attention on avoiding overdiagnosis among certain populations (e.g., high SES) may be advisable to address
thyroid cancer in Texas. Clinicians are encouraged to adhere to ATA/NCCN guidelines when choosing patients
for thyroid ultrasound, selecting which nodules to examine, and deciding which patients should proceed
to biopsy.
Introduction
Although thyroid cancer is a relatively rare carcinoma,several studies support rising incidence over the last few
decades in the United States (1–6). A number of factors have
been cited for these increases (7–9), most prominently, im-
provements in diagnostic practices (e.g., the use of ultrasound
with fine needle aspiration biopsies) resulting in an increased
ability to detect smaller tumors (1,10,11). Several studies
have suggested that diagnostic improvements cannot wholly
account for observed incidence trends, indicating a potential
role for other factors such as increased environmental or
hormonal exposures (8,12–16). However, a lack of concomi-
tant increases in thyroid cancer mortality and evidence of a
relatively high subclinical reservoir of occult papillary thyroid
cancers suggests that the bulk of rising incidence rates are
most likely attributable to the enhanced detection of small,
asymptomatic thyroid cancers (1,17–19). If so, it is likely that
increases in thyroid cancer incidence (particularly of small
tumors) would be pronounced among segments of the
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population with greater access to improved diagnostic tech-
nology, such as among patients of higher socioeconomic sta-
tus (SES). Recent research conducted with the National
Cancer Institute (NCI)’s Survival, Epidemiology and End
Results (SEER) 9 data supports this possibility (12). However,
additional research with other data sources is needed to
substantiate these findings, and to understand better whether
these associations are universal or are restricted to non-
Hispanic white patients. This research is important inasmuch
as rising incidence trends may at least partially reflect the
overdiagnosis of thyroid carcinomas that would otherwise
not elicit symptoms or require clinical intervention.
Thyroid cancer incidence in the United States is known to
vary by race (14,20). Unlike many other types of cancer,
however, thyroid cancer incidence is higher among whites
than among blacks (14,20), although both racial groups have
experienced increasing incidence trends in recent years
(14,21). Although incidence differences may reflect true
racial/ethnic dissimilarities in disease rates, SEER data indi-
cate that thyroid cancer incidence among whites (including
Hispanics) is rising more sharply than the incidence among
blacks (including Hispanics), particularly from the late 1990s
onward (1975–2009 data) (22). This pattern suggests the pos-
sibility of overdiagnosis of thyroid cancers among whites due
to potentially better access to new diagnostic technologies or
healthcare (23). Higher SES and accompanying health insur-
ance coverage may contribute to a higher likelihood of referral
for diagnostic procedures in response to the potentially am-
biguous symptoms of thyroid cancer (10), and these factors
may be more relevant to whites than blacks and patients
of other racial/ethnic minority groups. Although several re-
cent studies have focused on racial/ethnic or socioeconomic
differences in thyroid incidence, few examine both race/
ethnicity and SES in conjunction with one another [notable
exceptions include Morris et al. (23) and Brown et al. (24)], and
additional research is needed to tease apart their relations
better with incidence trends.
Cancer registries in the United States do not collect
individual-level SES information of cases. Therefore, registry-
based studies examining SES trends in cancer incidence and
cancer survival generally use county-level (10,12) or zip-code-
level (23) economic data to estimate SES information for cases.
However, counties and even zip codes tend to be rather large
areas with a great deal of economic diversity that is masked in
a combined average estimate of residents’ SES. On the other
hand, census tracts are smaller statistical subdivisions aver-
aging about 4000 residents each that were originally designed
to be homogeneous in terms of population characteristics in-
cluding residents’ SES (25). Census tracts have been sup-
ported as suitable proxies for neighborhoods in previous
research (26,27), and neighborhood-level SES has been used as
a proxy for individual-level SES in previous studies (28).
Therefore, compared to county- and zip-code-level estimates,
SES data generated at the census tract level may be more
representative of the individual-level SES of the inhabitants,
and may be a more relevant estimate of patients’ SES. How-
ever, we are aware of no previous studies on socioeconomic
trends in thyroid cancer incidence conducted in the United
States that have used this potentially more representative
conceptualization of SES.
In addition, many previous studies focused on trends in
thyroid cancer incidence have used national data from the
SEER database (12,23), which focuses on certain states and
geographical regions not including Texas or its metropolitan
areas. Consequently, to the best of our knowledge, trends
over time in thyroid cancer incidence by SES have not been
previously examined using Texas Cancer Registry data. Sig-
nificantly, Texas has the highest uninsurance rates, with 31%
of adult Texans living without health insurance coverage (29).
Given documented associations between health insurance
coverage and thyroid cancer incidence (10,23), it is of interest
to examine socioeconomic trends in thyroid cancer incidence
in Texas inasmuch as SES-based incidence differences attrib-
utable to detection biases might be particularly pronounced in
this state. Moreover, because these relations may operate
differently within racial/ethnic groups due to differing access
to care issues (e.g., uninsurance rates in Texas are 37% for
Hispanics, 21.4% for blacks, and 13.5% for whites) (30), it is
also of interest to examine socioeconomic-based trends in
thyroid cancer incidence among Texans by race/ethnicity.
The examination of socioeconomic trends in cancer incidence
by race/ethnicity in a single (but relatively large) state such as
Texas is particularly appropriate given recent findings citing
interactions of race/ethnicity and geographic region in thy-
roid cancer survival outcomes using the 17-region national
SEER database (31), which may also be relevant to thyroid
cancer incidence.
The current study was designed to examine trends in thy-
roid cancer incidence in Texas from 1995 to 2008 by SES, for
the population as a whole and by racial/ethnic group, using
census-tract-level data as a proxy for individual-level SES.
First, we were interested in better understanding whether
increases in incidence over time appeared attributable to a
true increase in disease rates, which might be suggested by
similarly increasing incidence among low and high SES
groups, or to a potential detection bias whereby increases in
incidence over time were largely attributable to the high SES
group. Second, we were interested in how racial/ethnic
trends in incidence by SES might further enhance our un-
derstanding of rising incidence. A better understanding of the
potential factors underlying increasing thyroid cancer inci-
dence is important, as resulting information can help to guide
future efforts toward delineating and preventing disease-
related causal factors (in the case of true disease increases) or
focusing clinical attention on avoiding overdiagnosis among
certain segments of the population (in the case of a detec-
tion bias).
Materials and Methods
Human subjects study approval
The University of Texas MD Anderson Cancer Center In-
stitutional Review Board and the Texas Department of State
Health Services Institutional Review Board approved this
study.
Data sources and variables
Thyroid cancer incidence data were provided by the Texas
Department of State Health Services from the Texas Cancer
Registry, which has achieved an annual ‘‘gold’’ certification
from the North American Association of Central Cancer Re-
gistries based on their standards for data completeness, ac-
curacy, and timeliness. Provided data were based on the
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International Classification of Diseases for Oncology code
C73.9. These data were available for each year beginning in
1995 and concluding in 2008. Data provided from this source
included the following information: race/ethnicity, sex, age at
diagnosis, cancer identification information (histologic type),
stage, and identification information regarding the census
tract of residence at the time of diagnosis. In addition, tumor
size data were made available, but approximately half of the
cases were missing these data. Previous research suggests that
the rising incidence in thyroid cancers is largely attributable to
the papillary type (1,2,6,10,13). However, we elected to in-
clude all histologic types in the current study because of the
potential for detection disparities to affect all histologic types,
to account for any potential histologic misclassification, and to
maximize the sample size. A similar approach has been taken
in previous literature (12).
The individual-level SES of thyroid cancer cases was not
part of registry information, and had to be estimated based on
area-level information. The U.S. census tract of residence at
the time of diagnosis was used to procure the relevant SES
information. First, all tracts in Texas were ranked based on
median household income from the 2000 U.S. census. The
2000 U.S. census information was used because it was the only
decennial census data collection that was conducted during
the span of time relevant to the cancer incidence data (1995–
2008). Next, we categorized each tract as a ‘‘low SES’’ or ‘‘high
SES’’ tract. The low SES tracts represented those in the lowest
quartile of median household income (range = $0–$27,803;
mean – SD = $21,761 – $5280), whereas the high SES tracts re-
presented the remaining tracts (i.e., those tracts within the top
75% of median household income; range = $27,803–$200,001;
mean – SD = $47,658 – $20,946). This procedure is similar to
other work in the area (12), and is intended to target tracts
that are particularly socioeconomically disadvantaged. The
use of area-level median household income as an indicator of
SES is supported by its relation with thyroid incidence in
previous work (10,12). The designation of census tracts as
low or high SES was then linked back to the incidence data
based on the residential census tract identifier for each inci-
dence case.
Data preparation
To prepare data for analysis, we calculated age-standardized
incidence by race/ethnicity based on 2000 U.S. census tract-
level population estimates per recommendations in the liter-
ature (32). Age adjustments were made based on 18 age
groups (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–
44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84,
‡ 85 years). There were 134 cases missing information on
race/ethnicity, and an additional four cases that could not be
matched to viable census tracts. These cases were excluded
from these calculations and subsequent analyses.
Data analyses
Incidence calculations, descriptive statistics, and prelimi-
nary analyses were performed using SAS v9.3 (SAS Institute
Inc., Cary, NC). Preliminary analyses included chi-square
tests to examine for significant differences in demographic
and clinical variables by SES group. Joinpoint regression an-
alyses were used to examine incidence trends over time by
SES for the whole study population and by race/ethnicity.
Joinpoint regression examines the statistical significance of
trends as well as the annual percentage change (APC) across
segments with 95% confidence intervals (CI). Joinpoint ana-
lyses were performed using the NCI’s Joinpoint Regression
Program v3.5.4 (33). Results were examined for the presence
of joinpoints (adjacent segments denoting significant changes
in incidence over time) and for significant APCs by SES.
p-Values of £ 0.05 were considered statistically significant.
Several exploratory analyses were conducted to follow up
the main analyses as described above. First, in order to ex-
plore temporal trends in a different way, we also broke the
study years into two equal time periods—T1 1995–2001, and
T2 2002–2008—and reran main joinpoint analyses to examine
trends within each time period. Next, because readers might
be interested in how relations between SES and incidence
trends varied by sex and by cancer histology, we reran the
main analyses: (i) stratified by sex, and (ii) for papillary his-
tology cases only (presentation by other histology type was
precluded due to small case numbers).
Results
Study population
There were 22,390 thyroid cancer cases from 1995 to 2008.
As expected, the majority of patients were female (75.7%) and
non-Hispanic white (65.0%). Approximately 24.3% of patients
were Hispanic, and 6.7% were non-Hispanic black. The re-
maining patients (4.1%) comprised Asian, American Indian,
and several other racial/ethnic groups. Patients resided
within 4076 of the 4388 census tracts within Texas, with the
number of cases per tract ranging from 1 to 49. The majority of
cases (84.3%) were from high SES tracts.
When cancer cases were categorized by histological cate-
gory, 85.9% (18,397) were papillary (ICD codes 8050, 8052,
8130, 8260, 8340–8344, 8450, 8452), 10.7% (2291) were follic-
ular (ICD codes 8290, 8330–8332, 8335), 2.5% (528) were
medullary (8345, 8346, 8510), and 0.9% (190) were anaplastic
(8021). In addition to those falling into the four major histo-
logical categories, there were 984 additional thyroid cancer
cases of other histological types. Unfortunately, there was a
significant amount of missing data for tumor size (50.4%),
limiting our ability to examine racial/ethnic trends in inci-
dence by SES over time based on these factors, which is an
issue not uncommon among other state-based incidence
studies (10). When cases from each year were collapsed into a
single group, chi-square tests indicated statistically significant
differences in age, sex, race/ethnicity, tumor size, and tumor
stage by SES (see Table 1 for participant characteristics and
differences by SES). Due to the relatively low incidence of
thyroid cancer among Asian/other races, all racial/ethnic
analyses included only the non-Hispanic white, non-Hispanic
black, and Hispanic cases.
Main analyses
The study population (which included Asian/other cases)
demonstrated an expected increase in thyroid cancer inci-
dence over the study period among cases from both low and
high SES areas, as indicated by positive incidence slopes in
both groups. Among the low SES group, thyroid cancer in-
cidence increased from 4.7 per 100,000 [CI 4.0–5.4] in 1995 to
8.9 per 100,000 [CI 8.0–9.9] in 2008. Incidence among the high
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SES group increased from 5.0 per 100,000 [CI 4.6–5.3] in 1995
to 13.8 per 100,000 [CI 13.2–14.3] in 2008. There were no
joinpoints among the low SES cases, indicating a steady in-
crease over time (APC = 6.7%, p < 0.05). However, two join-
points emerged among the high SES cases between 1995 and
1999. Specifically, the APC between 1995 and 1998 was 1.9%
( p > 0.05), which jumped to 26.5% ( p > 0.05) from 1998 to 1999,
and returned to a less pronounced but statistically significant
steady 8.6% ( p < 0.05) increase in incidence from 1999 to 2008.
A parallelism test indicated that the joinpoint projected inci-
dence trends between low and high SES groups were signif-
icantly different from one another ( p = 0.047).
Table 1. Characteristics of Patients with Thyroid Cancer: Texas Cancer Registry Data, 1995–2008
Characteristics Total cases [n (%)] SES-low cases [n (%)] SES-high cases [n (%)] SES differences (p-value)
Age < 0.001
< 45 years 9464 (42.3) 1365 (38.9) 8099 (42.9)
‡ 45 years 12,926 (57.7) 2148 (61.1) 10,778 (57.1)
Sex < 0.001
Male 5448 (24.3) 728 (20.7) 4720 (25.0)
Female 16,942 (75.7) 2785 (79.3) 14,157 (75.0)
Race/Ethnicity < 0.001
Non-Hispanic white 14,460 (65.0) 1054 (30.1) 13,406 (71.5)
Non-Hispanic black 1484 (6.7) 465 (13.3) 1019 (5.4)
Hispanic 5400 (24.3) 1920 (54.8) 3480 (18.6)
Asian/other 912 (4.1) 65 (1.9) 847 (4.5)
Thyroid tumor size < 0.001
£ 1 cm 3773 (34.0) 488 (28.6) 3285 (34.9)
> 1–2 cm 3008 (27.1) 451 (26.5) 2557 (27.2)
> 2–4 cm 2963 (26.7) 468 (27.5) 2495 (26.5)
> 4 cm 1361 (12.3) 297 (17.4) 1064 (11.3)
Missing tumor size 0.158
No 11,105 (49.6) 1704 (48.5) 9401 (49.8)
Yes 11,285 (50.4) 1809 (51.5) 9476 (50.2)
Thyroid tumor stage < 0.001
In situ/local 14,080 (68.7) 2022 (63.7) 12,058 (69.6)
Regional 5334 (26.0) 880 (27.7) 4454 (25.7)
Distant 1096 (5.3) 273 (8.6) 823 (4.8)
Missing tumor stage 0.004
No 20,510 (91.6) 3175 (90.4) 17,335 (91.8)
Yes 1880 (8.4) 338 (9.6) 1542 (8.2)
Whole sample 22,390 3513 (15.7) 18,877 (84.3)
Socioeconomic status (SES) was calculated based on quartiles of median household income at the census tract level using 2000 U.S. census
data. SES-low represents case representation in the first quartile of statewide median household income, whereas SES-high represents case
representation in the remaining three quartiles. Significant differences between SES groups were assessed using chi-square tests.
Table 2. Age-Adjusted Incidence Rate per 100,000 for Thyroid Cancer by Socioeconomic Status
and Race/Ethnicity, 1995–2008
SES-low SES-high
White Black Hispanic White Black Hispanic
Year AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI]
1995 6.37 [4.81–7.92] 3.68 [2.28–5.08] 4.23 [3.29–5.17] 5.61 [5.16–6.07] 2.56 [1.58–3.53] 4.73 [3.81–5.65]
1996 5.55 [4.07–7.03] 3.03 [1.73–4.33] 3.52 [2.68–4.37] 5.99 [5.52–6.46] 2.19 [1.38–3.00] 4.52 [3.66–5.37]
1997 5.94 [4.40–7.47] 3.79 [2.35–5.22] 5.41 [4.33–6.50] 5.72 [5.26–6.18] 3.07 [2.04–4.10] 4.22 [3.40–5.03]
1998 4.93 [3.50–6.36] 3.47 [2.11–4.84] 5.08 [4.05–6.12] 6.14 [5.66–6.62] 3.37 [2.32–4.42] 4.40 [3.55–5.26]
1999 6.07 [4.49–7.65] 4.24 [2.72–5.76] 6.45 [5.27–7.62] 7.15 [6.64–7.67] 3.62 [2.52–4.72] 6.73 [5.68–7.78]
2000 5.28 [3.82–6.73] 5.86 [4.09–7.63] 5.41 [4.37–6.46] 8.03 [7.48–8.57] 3.59 [2.47–4.70] 6.70 [5.67–7.73]
2001 7.01 [5.36–8.67] 4.73 [3.11–6.35] 6.63 [5.45–7.81] 8.08 [7.53–8.62] 4.22 [2.99–5.46] 6.84 [5.80–7.88]
2002 6.69 [5.05–8.33] 3.93 [2.47–5.40] 7.79 [6.48–9.11] 9.38 [8.79–9.97] 6.02 [4.57–7.47] 8.98 [7.73–10.23]
2003 6.56 [4.97–8.16] 5.05 [3.39–6.71] 6.61 [5.40–7.82] 9.69 [9.09–10.29] 6.62 [5.14–8.10] 9.54 [8.28–10.79]
2004 9.04 [7.18–10.89] 5.10 [3.43–6.77] 7.81 (6.53–9.10) 10.72 [10.09–11.35] 6.96 [5.42–8.49] 10.74 [9.37–12.12]
2005 9.49 [7.56–11.43] 7.33 [5.31–9.35] 9.30 [7.87–10.74] 11.77 [11.11–12.43] 8.94 [7.16–10.72] 11.15 [9.77–12.53]
2006 8.29 [6.54–10.04] 5.02 [3.35–6.68] 10.26 [8.74–11.77] 12.41 [11.73–13.08] 9.52 [7.70–11.33] 13.59 [11.99–15.19]
2007 9.03 [7.18–10.87] 5.67 [3.91–7.43] 11.06 [9.51–12.60] 13.04 [12.36–13.73] 7.78 [6.21–9.36] 13.89 [12.32–15.45]
2008 9.30 [7.40–11.20] 4.63 [3.04–6.21] 10.75 [9.23–12.27] 13.94 [13.22–14.65] 10.96 [8.97–12.95] 15.28 [13.67–16.90]
AAIR, age-adjusted incidence rate per 100,000; CI, 95% confidence interval.
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There was an increase in thyroid cancer incidence within
each of the racial/ethnic-specific SES subgroups as well. In-
cidence among the low SES groups per 100,000 in 1995 and
2008 respectively by racial/ethnic subgroup were as follows:
non-Hispanic white 6.4 [CI 4.8–7.9] and 9.3 [CI 7.4–11.2], non-
Hispanic black 3.7 [CI 2.3–5.1] and 4.6 [CI 3.0–6.2], and His-
panic 4.2 [CI 3.3–5.2] and 10.8 [CI 9.2–12.3]. Among the
high SES groups, incidence per 100,000 in 1995 and 2008 re-
spectively by racial/ethnic subgroup were as follows: non-
Hispanic white 5.6 [CI 5.2–6.1] and 13.9 [CI 13.2–14.7],
non-Hispanic black 2.6 [CI 1.6–3.5] and 11 [CI 9–13], and
Hispanic 4.7 [CI 3.8–5.6] and 15.3 [CI 13.7–16.9]. Age-adjusted
incidence rates by SES and race/ethnicity for all study years
are summarized in Table 2. No joinpoints emerged among the
non-Hispanic white, non-Hispanic black, or Hispanic cases in
either the low or the high SES groups. However, the results
indicate that whereas non-Hispanic whites experienced a
steady increase in incidence over time among both high
and low SES groups (combined APC = 7.6%, p < 0.05), non-
Hispanic blacks and Hispanics of higher SES had a much
more pronounced increase in incidence over time relative to
non-Hispanic blacks (black low SES APC = 4.1% vs. high SES
APC = 12.8%, p < 0.05) and Hispanics of lower SES (Hispanic
low SES APC = 8.3% vs. high SES APC = 11.2%; p < 0.05).
Parallelism tests indicate that the joinpoint projected inci-
dence trends between low and high SES groups were signif-
icantly different from one another in the non-Hispanic black
( p < 0.001) and Hispanic ( p = 0.004) subgroups, but not in the
non-Hispanic white subgroup ( p = 0.064).
Trends over time in thyroid cancer incidence by SES for the
whole study population and by race/ethnicity are displayed
in Figure 1.
Exploratory analyses
Exploratory analyses included an examination of joinpoint
incidence trends in T1 (1995–2001) and T2 (2002–2008). For the
whole population, results indicated a steady increase in inci-
dence over time among both high and low SES groups during
both time periods (T1 combined APC = 7.9%, p < 0.05; T2
combined APC = 7.6%, p < 0.05), and the incidence trends be-
tween groups were considered parallel ( p ‡ 0.31). Likewise,
for non-Hispanic blacks, results indicated a steady increase in
incidence over time among both high and low SES groups
FIG. 1. Results from joinpoint regression models on thyroid cancer incidence trends in Texas, 1995–2008, by socioeconomic
status (SES; high [black], low [gray]) for (A) the whole study population, and within three major racial/ethnic groups: (B)
non-Hispanic white, (C) non-Hispanic black, and (D) Hispanic. *Statistically significant annual percent change (APC) at
p < 0.05 in the joinpoint regression analyses.
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during both time periods (T1 combined APC = 9.2%, p < 0.05;
T2 combined APC = 7.2%, p < 0.05), with parallel incidence
trends ( p ‡ 0.45). However, trends for non-Hispanic whites
were not parallel between SES groups ( p £ 0.014), with the low
SES APC = 0.5% ( p > 0.05) and the high SES 7.5% ( p < 0.05)
during T1 and the low SES APC = 5.1% ( p < 0.05) and the high
SES 7.2% ( p < 0.05) during T2. Among Hispanics, the low SES
group had a steady increase of 9.0% ( p < 0.05) during T1,
whereas the high SES group had three joinpoints (1995–1998
APC = 3.0%; 1998–1999 APC = 58.6%; 1998–2001 APC = 0.3%;
p > 0.05). These trends were not parallel ( p < 0.02). However,
trends were parallel during T2 for Hispanic cases ( p = 0.46),
with a combined APC of 9.1% ( p < 0.05) among both the high
and low SES groups.
Sex-stratified analyses also reflected the increase in thyroid
cancer incidence over the study period among cases from both
low and high SES areas. Age-adjusted incidence rates by SES
and sex for all study years are summarized in Table 3. Among
males, there were no joinpoints in either the low or high SES
groups (APC = 7.8%, p < 0.05), and the incidence trends be-
tween groups were considered parallel ( p = 0.33). Among fe-
males, there were no joinpoints among the low SES cases,
indicating a steady increase over time (APC = 6.5%, p < 0.05).
However, two joinpoints emerged among the high SES cases
between 1995 and 2000. Specifically, the APC between 1995
and 1998 was - 0.1% ( p > 0.05), which jumped to 20.9%
( p > 0.05) from 1998 to 2000, and returned to a less pro-
nounced but statistically significant steady 8.5% ( p < 0.05)
increase in incidence from 2000 to 2008. A parallelism test
indicated that the joinpoint projected incidence trends be-
tween low and high SES groups of female cases were signif-
icantly different from one another ( p = 0.048).
In sex-stratified, racial/ethnic subgroup analyses, no join-
points emerged for males of any race/ethnicity in either
the low or the high SES groups (white APC = 6.9%, p < 0.05;
black APC = 8.4%, p < 0.05; Hispanic APC = 9.4%, p < 0.05),
and the incidence trends between groups were considered
parallel ( p ‡ 0.09). Likewise, there were no joinpoints among
Hispanic females of either SES group (APC = 9.8%, p < 0.05;
trends were parallel, p > 0.05). Among non-Hispanic white
females, however, there were no joinpoints among the low
SES cases (APC = 3.6%, p < 0.05), but two joinpoints among
the high SES cases (APC 1995–1998 = - 1.2%, p < 0.05; APC
1998–2000 = 18.9%, p > 0.05; APC 2000–2008 = 7.0%, p < 0.05;
trends not parallel, p < 0.05). Whereas trends among non-
Hispanic black females were devoid of joinpoints, those of
higher SES had a much more pronounced increase in inci-
dence over time relative to those of lower SES (high SES
APC = 13.0% vs. low SES APC = 3.9%, p < 0.05). A parallelism
test indicated that the joinpoint projected incidence trends
between low and high SES non-Hispanic black females
were significantly different from one another ( p < 0.001). Sex-
stratified trends over time in thyroid cancer incidence by
SES for the whole study population and by race/ethnicity
are displayed in Figures 2 and 3. Incidence rate ratios of thyroid
cancer by SES, sex, and race/ethnicity are displayed in Table 4.
Finally, histology-stratified analyses (papillary) were also
conducted. As with the whole population, no joinpoints
emerged among the low SES cases (APC = 7.4%, p < 0.05). Also
similarly, two joinpoints emerged among the high SES cases
between 1995 and 1999. Specifically, the APC between 1995
and 1998 was 1.5% ( p > 0.05), which increased markedly to
29.3% ( p > 0.05) from 1998 to 1999, and returned to a less
pronounced but statistically significant steady 9.5% ( p < 0.05)
increase in incidence from 1999 to 2008. A parallelism test
indicated that the joinpoint projected incidence trends be-
tween low and high SES groups were significantly different
from one another ( p < 0.006).
Racial/ethnic-specific SES subgroup analyses were also
conducted for papillary thyroid cancer. No joinpoints emerged
among the non-Hispanic black or Hispanic cases in either the
low or the high SES groups. Specifically, those of higher SES
had a more pronounced increase in papillary thyroid cancer
incidence over time relative to those of lower SES in both
racial/ethnic minority subgroups (black low SES APC = 6.4%
vs. high SES APC = 14.5%; Hispanic low SES APC = 8.5% vs.
Table 3. Age-Adjusted Incidence Rate per 100,000 for Thyroid Cancer Incidence
by Socioeconomic Status and Sex, 1995–2008
SES-low SES-high
By sex By sex
All Male Female All Male Female
Year AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI] AAIR [CI]
1995 4.71 [4.02–5.39] 1.79 [1.16–2.41] 7.41 [6.22–8.59] 4.96 [4.61–5.31] 2.62 [2.24–3.00] 7.25 [6.66–7.84]
1996 4.02 [3.39–4.66] 2.09 [1.41–2.78] 5.92 [4.85–6.99] 5.20 [4.84–5.56] 2.76 [2.36–3.15] 7.65 [7.05–8.25]
1997 5.04 [4.33–5.76] 2.32 [1.59–3.05] 7.67 [6.45–8.90] 5.09 [4.73–5.44] 3.19 [2.77–3.61] 6.97 [6.40–7.55]
1998 4.54 [3.86–5.22] 1.64 [1.05–2.23] 7.18 [5.99–8.36] 5.41 [5.05–5.78] 3.43 [3.00–3.87] 7.43 [6.83–8.02]
1999 5.72 [4.95–6.48] 2.45 [1.68–3.21] 8.97 [7.64–10.30] 6.56 [6.16–6.97] 4.09 [3.62–4.56] 9.04 [8.39–9.70]
2000 5.33 [4.60–6.05] 2.38 [1.64–3.11] 8.23 [6.97–9.48] 7.34 [6.91–7.76] 3.86 [3.40–4.31] 10.78 [10.06–11.49]
2001 6.47 [5.65–7.29] 3.82 [2.88–4.75] 8.99 [7.66–10.32] 7.52 [7.09–7.95] 4.15 [3.67–4.62] 10.80 [10.09–11.52]
2002 6.42 [5.61–7.23] 2.90 [2.09–3.71] 9.63 [8.26–10.99] 8.91 [8.44–9.38] 4.62 [4.11–5.14] 13.20 [12.41–13.99]
2003 6.20 [5.40–6.99] 2.62 [1.84–3.39] 9.59 [8.22–10.96] 9.31 [8.83–9.79] 4.75 [4.23–5.27] 13.81 [13.00–14.62]
2004 7.56 [6.68–8.43] 3.04 [2.20–3.87] 11.82 [10.31–13.34] 10.24 [9.73–10.74] 5.71 [5.14–6.28] 14.72 [13.88–15.56]
2005 8.67 [7.72–9.62] 5.14 [4.03–6.25] 12.18 [10.63–13.73] 11.30 [10.77–11.83] 6.26 [5.67–6.84] 16.19 [15.31–17.07]
2006 8.37 [7.44–9.29] 3.88 [2.94–4.83] 12.48 [10.92–14.03] 12.14 [11.59–12.69] 5.75 [5.19–6.32] 18.28 [17.35–19.22]
2007 9.31 [8.34–10.29] 3.96 [3.01–4.91] 14.25 [12.59–15.91] 12.75 [12.19–13.32] 6.81 [6.19–7.43] 18.56 [17.62–19.51]
2008 8.92 [7.96–9.87] 4.04 [3.08–4.99] 13.49 [11.87–15.11] 13.76 [13.17–14.34] 7.15 [6.52–7.78] 20.19 [19.20–21.17]
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high SES APC = 12.0%; p < 0.05). This pattern of results was
similar to those indicated earlier for analyses including all
histology types. Among the non-Hispanic white papillary
cases, however, two joinpoints emerged among both the low
and high SES groups. For the low SES papillary cases, the APC
between 1995 and 1999 was - 3.5% ( p > 0.05), which increased
markedly to 10.2% ( p < 0.05) from 1999 to 2005, which de-
creased to - 3.0% ( p > 0.05) from 2005 to 2008. For the high
SES papillary cases, the APC between 1995 and 1998 was 0.9%
( p > 0.05), which increased markedly to 26.3% ( p > 0.05) from
1998 to 1999, and returned to a less pronounced but statisti-
cally significant steady 8.5% ( p < 0.05) increase in incidence
from 1999 to 2008. Parallelism tests indicated that the join-
point projected incidence trends between low and high SES
groups were significantly different from one another in the
non-Hispanic black ( p < 0.003), Hispanic ( p = 0.031), and non-
Hispanic white subgroups ( p = 0.024).
Discussion
The current study is the first to examine SES-based trends
in thyroid cancer incidence over time in Texas using economic
information generated at the census tract level. The goal of the
study was to examine the impact of SES on thyroid cancer
detection from 1995 to 2008 in this state in order to understand
the basis of rising incidence rates better. Moreover, we also
investigated the nature of these relations within three major
racial/ethnic groups (non-Hispanic white, non-Hispanic
black, and Hispanic) to characterize further the nature of SES-
based trends in rising thyroid cancer incidence.
With regard to SES-based incidence trends within the
whole study population, we found steady annual incidence
increases of 6.7% from 1995 to 2008 among the low SES,
whereas trends among higher SES cases were more variable
(from 1995 to 1998) but ultimately steeper with annual inci-
dence increases of 8.6% from 1999 to 2008. The relatively
steeper increase among the high SES group relative to the low
SES group suggests that higher SES Texans may experience a
greater likelihood of thyroid cancer diagnosis than lower SES
Texans. The development and use of more sophisticated di-
agnostic technologies for thyroid cancer began in the late
1990s through early 2000s. This shift to the use of ultrasound
with fine needle aspiration biopsies enabled the detection of
smaller, nonsymptomatic thyroid carcinomas than was pre-
viously possible via palpitation alone, and several studies
have indicated the increased incidence of smaller tumors in
FIG. 2. Results from sex-stratified joinpoint regression models on thyroid cancer incidence trends among females in Texas,
1995–2008, by SES (high [black], low [gray]) for (A) the whole study population, and within three major racial/ethnic groups:
(B) non-Hispanic white, (C) non-Hispanic black, and (D) Hispanic. *Statistically significant APC at p < 0.05 in the joinpoint
regression analyses.
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recent years (1,2,12,16). Because the gaps between incidence in
the high SES and low SES groups seem to widen with time,
particularly among non-Hispanic white and non-Hispanic
black women, these results suggest the potential of a detection
bias whereby higher SES Texans have better access to en-
hanced diagnostic technologies than their lower SES coun-
terparts. As many smaller tumors may be initially detected
incidentally as part of other medical procedures (34), part of
that gap may reflect that higher SES patients may be more
likely to seek (or have access to) healthcare services in general
as compared to those of lower SES. Unlike many cancers,
however, early detection is controversial, and there is cur-
rently debate in the field about the necessity of intervention
with the small, asymptomatic tumors that may be significant
contributors to rising thyroid cancer rates (35). Because thy-
roid cancer treatment carries health risks and may ultimately
impact patients’ quality of life, it is important that clinicians
follow treatment guidelines promulgated by the American
Thyroid Association and National Comprehensive Cancer
Network. More research is necessary to inform these guide-
lines further to prevent potentially unnecessary treatment of
tumors that are small, asymptomatic, and detected serendi-
pidously or secondarily to other presenting problems.
Although results indicate that higher SES Texans are di-
agnosed with thyroid cancer at higher rates than lower SES
Texans, there was a steadily higher incidence of thyroid
cancer seen within both SES groups over time. Similar pat-
terns between low and high SES groups (defined by county-
level SES) have been found using SEER registry data focused
on other parts of the country (12). The current study adds to
this literature using a potentially more representative mea-
sure of SES (tract-level SES), and extends findings to Texas,
which is not represented in SEER registry data. These con-
verging data appear to support the ubiquity of rising inci-
dence rates. Several prior studies have reviewed potential
reasons for these increases, including increased environ-
mental or hormonal exposures (8,12–16). However, identi-
fiable contributors to true, significant increases in thyroid
cancer incidence remain elusive. Given the lack of concom-
itant increases in thyroid cancer mortality in recent years
(1,17,21), and the relatively high level of subclinical occult
papillary thyroid cancers identified in previous autopsy re-
search (18,36), the most parsimoneous explanation for rising
incidence rates appears to be enhanced detection rather than
true increases in disease rates (19). Nevertheless, additional
research focused on better understanding the basis for these
FIG. 3. Results from sex-stratified joinpoint regression models on thyroid cancer incidence trends among males in Texas,
1995–2008, by SES (high [black], low [gray]) for (A) the whole study population, and within three major racial/ethnic groups:
(B) non-Hispanic white, (C) non-Hispanic black, and (D) Hispanic. *Statistically significant APC at p < 0.05 in the joinpoint
regression analyses.
THYROID CANCER TRENDS IN TEXAS 563
steady and significant increases in incidence among all seg-
ments of the population is needed, as thyroid cancer is lit-
tle understood and fairly unique among carcinomas in this
regard.
The current study also allowed examination of the potential
for racial/ethnic differences in the rates of increasing inci-
dence trends between low and high SES groups over time. The
results indicate that whereas non-Hispanic whites experi-
enced a steady 7.6% annual increase in incidence over time
among both high and low SES groups, Hispanics of lower SES
had a less pronounced increase in incidence over time relative
to Hispanics of higher SES (8.3% vs. 11.2%). These differences
were even more marked among the non-Hispanic blacks, with
a 4.1% APC among the lower SES group versus a 12.8% APC
among the higher SES group. These results suggest that
enhanced detection among non-Hispanic blacks and His-
panics of higher SES are substantial contributors to the higher
incidence rates seen among higher SES Texans among the
population as a whole. Previous research suggested a lack
of disparities in clinical presentation of thyroid cancer (e.g.,
tumor size) between whites and blacks when both groups
had equal access to healthcare (24). However, the high rate of
uninsurance has been cited as one relevant factor that limits
the ability for low SES minorities to access healthcare (30), and
the particularly low incidence of thyroid cancers among low
SES non-Hispanic blacks and Hispanics may reflect this issue.
A previous study, for example, attributed approximately 50%
of the thyroid cancer incidence gap between blacks and
whites to racial disparities in health insurance coverage (23).
However, other factors may also be relevant. For example,
research in other areas of the country has linked residential
adjacency to metropolitan areas, where access to screening
and medical care may be better, with steeper increases in
thyroid cancer incidence trends relative to nonadjacency (12).
Therefore, it may also be that patterns of residential racial/
ethnic segregation may impact access to healthcare or health-
related resources among low SES minority groups due to a
greater likelihood of nonadjacency to those resources, result-
ing in lower thyroid incidence among lower SES minority
groups. Although thyroid cancer mortality rates are generally
low (especially for papillary, follicular, and medullary thyroid
cancers) (21) and some studies have failed to support racial
differences in mortality (23), the literature is mixed on this
point. For example, a recent study cited a recent 51% increase
in mortality among black patients versus white patients with
papillary and follicular thyroid cancers (31). Therefore, al-
though the incidence of thyroid cancers is relatively low
among racial/ethnic minority populations (particularly non-
Hispanic blacks) compared to non-Hispanic white popula-
tions, it seems there is a delicate balance to be struck between
avoiding overdiagnosis among high SES racial/ethnic mi-
nority patients and failing to diagnose and/or treat















1995 4.15 [2.83–6.09] 0.58 [0.37–0.91] 0.67 [0.48–0.93] 3.68 [2.04–6.63] 3.42 [1.29–9.06] 5.27 [2.77–10.01]
1996 2.83 [1.95–4.11] 0.55 [0.33–0.90] 0.63 [0.44–0.91] 2.95 [1.62–5.39] 2.67 [0.97–7.31] 3.08 [1.67–5.66]
1997 3.30 [2.32–4.70] 0.64 [0.40–1.01] 0.91 [0.66–1.26] 3.30 [1.82–6.00] 4.75 [1.64–13.76] 2.93 [1.76–4.86]
1998 4.39 [2.95–6.52] 0.70 [0.43–1.15] 1.03 [0.72–1.47] 3.66 [1.80–7.44] 4.14 [1.42–12.08] 4.55 [2.60–7.96]
1999 3.67 [2.59–5.19] 0.70 [0.45–1.09] 1.06 [0.77–1.46] 3.81 [2.04–7.13] 6.94 [2.09–23.03] 2.86 [1.79–4.56]
2000 3.46 [2.45–4.88] 1.11 [0.74–1.67] 1.03 [0.73–1.44] 6.00 [2.79–12.87] 2.92 [1.40–6.12] 2.67 [1.66–4.29]
2001 2.36 [1.77–3.13] 0.67 [0.44–1.02] 0.95 [0.70–1.27] 2.57 [1.52–4.35] 1.50 [0.72–3.11] 2.69 [1.78–4.06]
2002 3.32 [2.43–4.55] 0.59 [0.38–0.92] 1.17 [0.87–1.57] 3.45 [1.92–6.19] 3.18 [1.19–8.47] 3.39 [2.21–5.20]
2003 3.66 [2.64–5.10] 0.77 [0.51–1.16] 1.01 [0.74–1.36] 3.64 [2.03–6.53] 2.04 [0.97–4.28] 4.55 [2.72–7.62]
2004 3.89 [2.87–5.27] 0.56 [0.38–0.83] 0.86 [0.66–1.12] 3.12 [1.94–5.02] 5.47 [1.91–15.62] 3.97 [2.52–6.24]
2005 2.37 [1.84–3.05] 0.77 [0.55–1.09] 0.98 [0.76–1.27] 1.77 [1.16–2.70] 2.09 [1.10–3.96] 2.95 [1.99–4.38]
2006 3.21 [2.44–4.23] 0.61 [0.41–0.90] 1.24 [0.96–1.60] 2.10 [1.33–3.30] 3.12 [1.34–7.26] 4.08 [2.70–6.15]
2007 3.60 [2.75–4.70] 0.63 [0.43–0.91] 1.22 [0.96–1.57] 2.24 [1.45–3.48] 3.84 [1.69–8.72] 5.49 [3.60–8.36]
2008 3.34 [2.56–4.35] 0.50 [0.33–0.74] 1.16 [0.90–1.48] 2.68 [1.70–4.24] 4.58 [1.76–11.88] 3.89 [2.69–5.62]
SES-high
1995 2.76 [2.34–3.27] 0.46 [0.31–0.67] 0.84 [0.68–1.04] 2.80 [2.32–3.38] 2.70 [1.06–6.84] 2.85 [1.70–4.78]
1996 2.77 [2.35–3.27] 0.37 [0.25–0.53] 0.75 [0.61–0.93] 2.66 [2.22–3.19] 1.55 [0.73–3.30] 5.67 [2.99–10.77]
1997 2.19 [1.87–2.55] 0.54 [0.38–0.76] 0.74 [0.60–0.91] 1.95 [1.64–2.31] 3.42 [1.58–7.41] 4.53 [2.75–7.48]
1998 2.16 [1.86–2.51] 0.55 [0.40–0.76] 0.72 [0.58–0.88] 2.10 [1.77–2.48] 7.07 [2.65–18.90] 2.38 [1.52–3.71]
1999 2.21 [1.93–2.53] 0.51 [0.37–0.69] 0.94 [0.79–1.12] 2.09 [1.79–2.44] 2.37 [1.11–5.08] 3.28 [2.26–4.77]
2000 2.79 [2.44–3.20] 0.45 [0.32–0.61] 0.83 [0.71–0.99] 2.74 [2.35–3.21] 1.93 [0.90–4.12] 3.30 [2.20–4.95]
2001 2.60 [2.28–2.97] 0.52 [0.39–0.71] 0.85 [0.72–1.00] 2.44 [2.09–2.83] 4.29 [2.15–8.53] 2.88 [1.96–4.23]
2002 2.85 [2.52–3.24] 0.64 [0.50–0.82] 0.96 [0.82–1.12] 2.83 [2.45–3.28] 1.67 [0.97–2.86] 3.09 [2.10–4.55]
2003 2.91 [2.57–3.29] 0.68 [0.54–0.86] 0.98 [0.85–1.14] 2.87 [2.48–3.31] 3.57 [1.98–6.45] 3.28 [2.33–4.61]
2004 2.58 [2.30–2.89] 0.65 [0.52–0.82] 1.00 [0.87–1.15] 2.32 [2.04–2.64] 5.91 [3.08–11.32] 3.41 [2.41–4.84]
2005 2.59 [2.32–2.88] 0.76 [0.62–0.93] 0.95 [0.83–1.08] 2.38 [2.11–2.70] 4.29 [2.48–7.41] 4.07 [2.92–5.68]
2006 3.18 [2.84–3.55] 0.77 [0.63–0.94] 1.10 [0.96–1.25] 2.98 [2.62–3.39] 3.19 [1.98–5.15] 3.62 [2.67–4.91]
2007 2.73 [2.46–3.03] 0.60 [0.48–0.74] 1.06 [0.94–1.21] 2.59 [2.30–2.92] 3.31 [1.94–5.62] 3.27 [2.46–4.35]
2008 2.82 [2.55–3.12] 0.79 [0.65–0.95] 1.10 [0.97–1.23] 2.84 [2.52–3.20] 3.52 [2.27–5.46] 2.75 [2.13–3.56]
IRR, incidence rate ratio.
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potentially aggressive tumors among lower SES racial/ethnic
minority patients due to healthcare access issues (cf. 19).
Analyses of SES-based incidence trends in thyroid cancer
incidence by tumor size could help to shed additional light on
the potential contribution of enhanced detection to rising
thyroid cancer incidence. If enhanced detection was influ-
encing increases, increased incidence of smaller tumor sizes
(e.g., £ 2 cm or £ 1 cm) would be expected, especially begin-
ning in the late 1990s with the emergence of new detection
technology. On the other hand, the incidence of large tumors
( > 4 cm) might decrease over time, assuming that diagnostic
improvements would have led to the earlier detection of tu-
mors in recent years (i.e., their detection at smaller sizes).
Unfortunately, one limitation of our registry data is that half
of the cases were missing tumor size data. Using the data
available to us, however, we conducted a post hoc investiga-
tion of SES-based trends in the proportion of incidence cases
by tumor size (see Table 5). In general, the results suggest that
enhanced detection (as evidenced by increasing proportion of
smaller tumors and decreasing proportion of larger tumors) is
contributing to observed patterns in this disease among the
population as a whole. However, an increase in the propor-
tional detection of tumors £ 2 cm among high and low SES
non-Hispanic blacks over time was not significant, nor was
the increase in the proportional detection of tumors £ 1 cm
among low SES non-Hispanic blacks. In addition, decreases in
the proportional detection of large tumors among Hispanics
over time were not significant. These findings may suggest
that racial/ethnic minority groups are not experiencing the
effects of enhanced diagnostic technologies for thyroid cancer
in the same way that non-Hispanic whites are. However,
because missing tumor data might not be missing at random,
and because of a small number of low SES cases for some
racial/ethnic subgroups, these results should be interpreted
with caution. The increased incidence of smaller tumors has
been supported in previous research (1,2,12,16). Contrary to
our findings, however, some studies indicate increases in the
incidence of large tumors too (21), though results tend to vary
between studies regarding the extent to which this growth
is contributing to overall incidence trends (1,16). More re-
search, particularly on racial/ethnic SES-based differences in
thyroid cancer incidence by tumor size, is needed to inform
the literature.
Finally, exploratory analyses included an examination of
SES and racial/ethnic trends by sex and histology. Not sur-
prisingly, given that the sample comprised 76% females and
86% papillary cancers, results from the main analyses were
largely driven by the females in the population and by the
papillary cancers. However, it is important to note that inci-
dence rates were steadily increasing over time among males
as well as females in the study population, and that incidence
rates among high SES non-Hispanic black females demon-
strated the most marked increases over time (13%), whereas
those among low SES non-Hispanic black females showed the
smallest rate of increase of any group (3.9%). These results
suggest that high SES non-Hispanic black females may be at
particular risk for overdiagnosis.
Limitations of the current study include the lack of in-
formation on several individual-level variables including
socioeconomic and health-related data (e.g., insurance
coverage status), which are common to registry-based
studies. Previous studies have used county-level estimates
of insurance coverage in analyses. However, we were un-
aware of any available insurance coverage data on the scale
used in the present study (i.e., tract level). Also, the use of
SES and population data from a single point in time (2000
U.S. census) is a limitation, given that incidence spanned
over a decade. As a result, incidence may be over- or un-
derestimated in some years due to population changes. The
inability to examine SES-based trends in cancer incidence
among Asian and other races is also a limitation, especially
given the relatively high incidence found among Asians
(particularly Filipinos) in previous studies (21). Finally,
lower incidence of follicular, medullary, and anaplastic
thyroid cancers prohibited SES and race/ethnicity-based
analyses by these histologic categories. Future studies with
greater sample sizes (e.g., using national data) may be used
to understand better how associations reported here might
vary by histology.
Similar to several recent studies in the field, our results also
support the rising incidence of thyroid cancer over recent
years (1–6,12). Comparing our results to those of previous
studies (10,12,21), however, it is of interest that thyroid cancer
incidence in Texas appears to be rising more steeply than in
other areas of the country. For example, a previous study
using similar methodology but at the county-level in SEER 9
registries found 4.0% annual incidence increases from 1980 to
2008 among low SES groups (vs. 6.7% in the current study)
and 6.6% annual incidence increases from 1997 until 2008
among high SES groups (vs. 8.6% in the current study) (12).
Likewise, racial/ethnic-specific trends in incidence were also
higher in the current sample than in previous studies (20). The
Table 5. Trends in the Proportion of Incidence
Cases by Tumor Size, 1997–2008
Annual percentage change
Tumor
size £ 1 cm
Tumor
size £ 2 cm
Tumor
size > 4 cm
Population
SES-low 2.0* 2.0* - 3.1*
SES-high 2.0* 2.0* - 3.1*
Non-Hispanic white
SES-low 4.5* 2.6* - 3.9*
SES-high 4.5* 2.6* - 3.9*
Non-Hispanic black
SES-low 4.0a 2.7 - 3.7*
SES-high 6.2a* 2.7 - 3.7*
Hispanic
SES-low 4.7* 1.5* - 0.2
SES-high 4.7* 1.5* - 0.2
Table reflects results from joinpoint analyses examining trends in
the proportion of incidence by tumor size, based on available data.
For example, the first column of data refers to changes in the
proportion of tumors size £ 1 cm relative to all other tumor sizes
diagnosed from 1997 to 2008. In all population and racial/ethnic
subgroup comparisons, the annual percentage change (APC) was the
same in the low and high SES groups (i.e., joinpoint regression lines
were parallel). The years 1995 and 1996 had to be excluded from
these analyses due to too few cases.
aThe year 1997 had to be additionally excluded from these
analyses due to too few cases.
*Statistically significant APC at p < 0.05 in the joinpoint regression
analyses.
THYROID CANCER TRENDS IN TEXAS 565
reasons behind these potential incidence trend differences are
not clear and beyond the scope of the current study. However,
geographic variations in thyroid cancer incidence, and factors
that might underlie these variations, might be worthy of fu-
ture investigation.
In summary, the current study is the first to examine
census-tract-level socioeconomic trends in thyroid cancer
incidence in Texas to understand better the causes of rising
incidence from 1995 to 2008. Results of the current study
suggest SES-based detection biases, whereby higher SES and
particularly higher SES non-Hispanic blacks and Hispanics
in Texas, may have increased access to new diagnostic
technologies relative to their lower SES counterparts. The
current study used a potentially more representative mea-
sure of SES to add to a growing literature elucidating the
connection between SES and thyroid cancer incidence
trends, and further delineated the nature of those relations in
racial/ethnic specific analyses. Although true underlying
causal processes cannot be depicted via the analysis of SES-
based trends in incidence, the relatively more indirect
methodology in this study is commonly used in the field to
explore potential contributors to incidence trends and for the
purposes of hypothesis-generation (12,23). Additional re-
search is needed to confirm whether the findings reported in
this study can be replicated in other areas of the nation.
However, results suggest that a dual focus on delineating
and preventing known disease-related causal factors (e.g.,
radiation exposure) and avoiding overdiagnosis among
certain populations (e.g., high SES) may be advisable ap-
proaches to address thyroid cancer in Texas. Clinicians are
encouraged to adhere to American Thyroid Association and
National Comprehensive Cancer Network guidelines when
choosing patients for thyroid ultrasound, selecting which
nodules to examine, and deciding which patients should
proceed to biopsy.
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